key: cord-0983041-btv4jnmb
authors: Wicky, Paul-Henri; d’Humières, Camille; Timsit, Jean-François
title: How common is ventilator-associated pneumonia after coronavirus disease 2019?
date: 2022-01-18
journal: Curr Opin Infect Dis
DOI: 10.1097/qco.0000000000000817
sha: 19fe2111b1540c0177678825788944070bc48481
doc_id: 983041
cord_uid: btv4jnmb

The first studies on COVID-19 patients with acute respiratory distress syndrome (ARDS) described a high rate of secondary bacterial ventilator-associated pneumonia (VAP). The specificity of VAP diagnoses in these patients are reviewed, including their actual rate. RECENT FINDINGS: Published studies described high rates of bacterial VAP among COVID-19 patients with ARDS, and these VAP episodes are usually severe and of specifically poor prognosis with high mortality. Indeed, Severe acute respiratory syndrome - coronavirus disease 19 (SARS-CoV2) infection elicits alterations that may explain a high risk of VAP. In addition, breaches in the aseptic management of patients might have occurred when the burden of care was heavy. In addition, VAP in these patients is more frequently suspected, and more often investigated with diagnostic tools based on molecular techniques. SUMMARY: VAP is frequented and of particularly poor prognosis in COVID-19 patients with ARDS. It can be explained by SARS-CoV-2 pathophysiology, and also breaches in the aseptic procedures. In addition, tools based on molecular techniques allow an early diagnosis and unmask VAP usually underdiagnosed by traditional culture-based methods. The impact of molecular technique-based diagnostics in improving antibacterial therapy and COVID-19 prognosis remain to be evaluated.

The outcome of acute respiratory distress syndrome (ARDS) because of COVID-19 is singularly worse when complicated with nosocomial pneumonia. Indeed, the relative risk of developing a lower respiratory tract infection (LRTI) has been reported to be 60% higher in these patients compared with patients with ARDS from other causes [1 && ]. Their prognosis is characterized by an increased crude mortality and a prolonged duration of mechanical ventilation by about 70 and 40%, respectively [2].

The reported incidence of ventilator-associated pneumonia (VAP) in COVID-19 ARDS, ranges from 25 to almost 85%, and represents twice as many complications as in control ARDS patients without COVID-19 (Table 1) [3] . In COVID-19 patients, VAP occurred earlier than in other mechanically ventilated patients [4] . Despite a relatively low rate of bacterial coinfection [5, 6, 7 & ], patients with COVID-19 pneumonia frequently receive antimicrobial therapy. Indeed, up to three out of four patients are treated with antimicrobials in the community setting [8] . In a large multicentric prospective cohort in the United Kingdom, 37% of patients were treated with antimicrobials before hospital admission, and 70.6% developed secondary infections, at least 48 h after admission [9]. Importantly, 85.2% received one or more ant-infective treatments at hospital despite the fact that significant bacteriological confirmation of co-infection was

Some differences in the incidence should be analysed according to the following considerations ( Fig. 1) . First, key aspects of the physiopathology of Severe acute respiratory syndrome -coronavirus disease 19 (SARS-CoV2)-induced pneumonia, such as altered coagulation and inherent immunothrombosis, may also specifically support a higher risk for pulmonary infarction. Second, disease-associated immune impairment could at least partly explain the propensity of developing VAP, also potentially driven by the use of immunomodulator therapies. The use of dexamethasone (DXM) might favor the occurrence of VAP and its recurrences. However, in a multicenter cohort study conducted during the first and second wave of COVID-19, Gragueb-Chatti et al.

[11] found that the cumulative incidence of VAP was not significantly different in patients treated with DXM or not. Although the use of antagonists of IL-6 receptors is associated with an increased risk of bacterial infections, large randomized studies did not unmask a significant increase of VAP risk [12, 13] . However, adverse event reporting was reduced in both platform trials and the reported cases of VAP in IL-6 receptor antagonists and control group were surprisingly low. Third, as compared with other ARDS, the increased incidence of VAP may be partially because of less rigorous use of standard prevention strategies during COVID-19 waves, more prolonged duration of mechanical ventilation, prolonged use of sedation, and more frequent need for prone position [14] .

Furthermore, the particularly high incidence of VAP should somehow be understood in light of the diagnostic criteria that are used, including the extensive use of new molecular methods. Indeed, VAP suspicion become very common, as patients with SARS-CoV2 ARDS often remain febrile, with prolonged alteration of PaO 2 /FiO 2 ratio. In those patients mechanically ventilated, with a high level of positive airway pressure, profoundly sedated, and who received paralytic agents, hemodynamic alteration and vasopressor need are also frequent. The worsening of hemodynamic or oxygenation status are generally considered as the most reliable criteria for suspecting VAP [15 && ]. Also, clinical criteria are usually fickle, and fever can be subdued especially with corticosteroids or extracorporeal membrane oxygenation (ECMO) [16] [17] [18] . Moreover, defining a new or worsening pulmonary infiltrate is of particular difficulty in patients with ARDS [19] .

The heterogeneity of sample techniques may also have an impact [20 (Table 1) . Fiberoptic bronchoscopy for bronchoalveolar lavage (BAL) during the COVID-19 pandemic has been variously performed. This procedure is at high risk of generating aerosol, thus carrying a potential hazard of exposure to the virus. Consequently, it has been scarcely used during the first pandemic wave [28] . Then, because of the reportedly low risk of virus dissemination, bronchoscopy has been more extensively used in intubated COVID-19 patients as compared with other ARDS patients [29] , also because COVID-19 patients with ARDS have frequent atelectasis [30] , related to obstructive mucosal secretions [31, 32] . The extensive use of bronchoscopy may have led to an overuse of bacteriological sampling, eventually contributing to overdiagnosis of VAP. Indeed, Maes et al. [20 && ] showed that patients with COVID-19 were more likely to be investigated for suspicion of VAP than other mechanically ventilated patients.

The generalization of molecular diagnostics methods can also explain an increase in the incidence of diagnosed VAP [33, 34] . Throughout the pandemic, diagnostic strategies changed towards a wider use of multiplex PCR (mPCR) techniques, which thus became preferred compared with the culture-based gold standard. They initially represented a key advantage in the laboratory setting

Incidence of ventilator-associated pneumonia (VAP) is higher in COVID-19 invasively ventilated patients than in patients with other causes of ARDS.

High VAP incidence is explained by COVID-19associated immune alteration, pulmonary infarction, as well as the extensive use of immunosuppressive agents. VAP in COVID-19 patients is frequently associated with treatment failure, abscess, empyema, and recurrences.

The use of multiplex PCR shortened the delay of bacterial identification and has been increasingly used during the COVID-19 pandemic. Its impact on appropriateness of antibacterial therapy and prognosis remains to be evaluated.

to limit healthcare workers exposition to the virus [35] , by providing rapid identification of bacteria and selected resistance mechanisms while avoiding Gram stain examination and other manual tests. The accuracy of available panels is low for some pathogens, and those techniques are only able to identify a limited number of pathogens [36] . Inversely, a positive PCR with negative cultures does not definitely demonstrate a respiratory infection. This discrepancy has been analysed in recent retrospective studies, and frequent misdiagnoses were identified with bacterial identification and negative cultures or positive cultures under the traditional diagnostic thresholds [ ] with a semi-quantitative household mPCR. In Bichat hospital, mPCR was used on clinical indication for suspicion of hospital-acquired pneumonia or VAP in mechanically ventilated patients with COVID-19 ARDS, and was positive for 48 episodes. However, for 5 of these episodes, the cultures remained negative (11%), and for 18 other episodes, the culture was positive but below the quantitative thresholds (10 4 CFU/ml for BAL and 10 3 CFU/ml for mini-BAL) [39 && ]. As for non-COVID patients [40, 41] , the significance of a positive mPCR test with negative culture (or below the threshold) remained speculative. It could correspond to a false-positive result that may artificially increase the incidence of VAP. But it might also represent a true positive, if new antimicrobials have been started for treatment of a new sepsis before bacteriological samples, and thus artefactually led to a negative culture [42] .

VAP diagnosed in COVID-19 patients is frequently associated with bloodstream infections [21 && ,43], ,44]. This particular severity argues against an overdiagnosis in available studies, which did not describe a specifically increased mortality.

The percentage of treatment failures and reported complications (Table 1) is a strong argument for the use of rapid and very sensitive diagnostic tests with a reduced turn-around time [45] . The mPCR panels also enable us to detect the presence of multi-resistant bacterial strains, and thus avoid the overuse of widespectrum molecules [40] . The association with lung perfusion abnormalities [46] raised the problem of impaired antibiotic diffusion, and eventually support the need to rely on therapeutic drug monitoring. In Table 1 , we summarize the most frequent complications observed in the main studies.

The true impact of VAP on outcome also remains unclear. No significant association with attributable overmortality has been reported so far [1 && ]. Still, COVID-19-associated and steroidinduced immunomodulation also implies superinfection because of other opportunistic pathogens. Patients treated with dexamethasone had reduced ICU length of stay, more ventilator-free days but similar mortality regardless of the timing of administration [48] . A true concern also exists about fungal superinfections that could be associated with lung abscesses. Screening for such diagnostic is warranted as they could occur in up to one-third of COVID-19 patients [49] . Consequently, alternative causes should be investigated that might be linked with an impaired prognosis, such as respiratory virusrelated nosocomial co-infections [50] .

In conclusion, the diagnosis of VAP remains challenging in COVID-19 patients with ARDS. The reported incidence is higher than that observed in other mechanically ventilated patients with or without ARDS. Poor infection control practices, local and systemic immune alterations, and extensive use of corticosteroids and immunosuppressive agents probably explain this result much more than an oversensitive diagnostic approach. Rapid molecular assays are instrumental in the timeliness and appropriateness of adequate antibiotic prescriptions [51] . Nonetheless, well conducted studies are needed to evaluate the impact of rapid diagnostic tests in the appropriateness of antimicrobial therapy in order to improve the prognosis of COVID-19 patients with ARDS [52] .

We would like to thank Celine Feger (MD) Emibiotech TM for her editorial assistance. 

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

Multidrug-resistant pathogens were isolated in 23.3%. 2. Nseir S, Martin-Loeches I, Povoa P, et al., coVAPid study group. Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort

Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes

Increased incidence of ventilator-acquired pneumonia in coronavirus disease 2019 patients: a multicentric cohort study

coVAPid study group. Early bacterial identification among intubated patients with COVID-19 or influenza pneumonia: a European Multicenter Comparative Cohort Study

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Interleukin-6 receptor antagonists in critically ill patients with Covid-19

Ventilator-associated pneumonia in the era of COVID-19 pandemic: how common and what is the impact?

The outcome of the 86% of patients developing VAP after COVID-19 ARDS under ECMO was assessed. A recurrence occurred in 79% of patients. Enterobacteriacae accounted for 70% of causative pathogens, whereas Pseudomonas aeruginosa for 37%. The median time of 10 days for VAP after admission

Nosocomial infections in adult cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation

Ventilator-associated pneumonia in extracorporeal membrane oxygenation-assisted patients

Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired/ventilatorassociated bacterial pneumonia clinical trials

Pulmonary infections complicating ARDS

Ventilator-associated pneumonia in critically ill patients with COVID-19

Among 81 COVID patients of this prospective study, 48% patients were diagnosed with VAP, and a cumulated incidence of 28/1000 ventilator-days, higher than the 144 non-COVID controls (13/1000). A key interest of this study in the methods used to confirm the infection, using real-time PCR (TaqMan array) as an alternative of BAL culture

Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French Region

An hospital from an uninundated region reported the incidence of patients referred from overcrowded area during the first wave. The cumulated incidence of VAP was particularly elevated (33.7/1000 ventilator-days), and characterized by a high prevalence of recurrences (20%)

Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to coronavirus 19 disease

Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study

Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study

Ventilator-associated pneumonia in COVID-19 patients: a retrospective cohort study

Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study

Causes and timing of death in critically ill COVID-19 patients

SARS-CoV-2 detection on bronchoalveolar lavage: an Italian Multicenter experience

Safety and efficacy of bronchoscopy in critically ill patients with coronavirus disease

Prevalence and clinical consequences of atelectasis in SARS-CoV-2 pneumonia: a computed tomography retrospective cohort study

Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients

Abnormal airway mucus secretion induced by virus infection

Ventilator-associated pneumonia in patients with COVID-19: a systematic review and meta-analysis

Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's Diagnostics Committee

Biological risk assessment: general considerations for laboratories

Molecular diagnostic methods for pneumonia: how can they be applied in practice?

Respiratory bacterial co-infections in intensive care unit-hospitalized COVID-19 patients: Conventional culture vs BioFire FilmArray pneumonia Plus panel

Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using Conventional Culture and BioFire, FilmArray Pneumonia Panel Plus Assay

Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit

The authors described the impact of multiplex PCR panel on antibiotic use for HAP/VAP affecting COVID-19 patients admitted in ICU. Positive tests resulted in initiation or adaptation of antibiotics in 44% of cases, and withdrawal in 19% when the test was negative

Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia

Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia

Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using ventilation

COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network

Hospital-acquired infections in critically ill patients with COVID-19

Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Among 161 patients with COVID-19 in this single-center study, 119 (73%) developed a VAP, and 17 (14%) a lung abscess. Pseudomonas aeruginosa accounted for 32% of species

OutcomeReaTM research network. Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: a multicenter cohort study of the OUTCOMEREA network

Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study

Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: a single-center retrospective study

Identification of bacterial co-detections in COVID-19 critically Ill patients by BioFire1 FilmArray1 pneumonia panel: a systematic review and meta-analysis

The challenge of ventilatorassociated pneumonia diagnosis in COVID-19 patients

Two original observations concerning bacterial infections in COVID-19 patients hospitalized in intensive care units during the first wave of the epidemic in France